| Membrane transporters in drug development KM Giacomini, SM Huang, DJ Tweedie, LZ Benet, KLR Brouwer, X Chu, ... Nature reviews Drug discovery 9 (3), 215, 2010 | 3610* | 2010 |
| Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review P Zhao, L Zhang, JA Grillo, Q Liu, JM Bullock, YJ Moon, P Song, SS Brar, ... Clinical Pharmacology & Therapeutics 89 (2), 259-267, 2011 | 559 | 2011 |
| Cloning and functional expression of a human liver organic cation transporter L Zhang, MJ Dresser, AT Gray, SC Yost, S Terashita, KM Giacomini Molecular pharmacology 51 (6), 913-921, 1997 | 511 | 1997 |
| The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies SU Yasuda, L Zhang, SM Huang Clinical Pharmacology & Therapeutics 84 (3), 417-423, 2008 | 456 | 2008 |
| New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process SM Huang, JM Strong, L Zhang, KS Reynolds, S Nallani, R Temple, ... The Journal of Clinical Pharmacology 48 (6), 662-670, 2008 | 439 | 2008 |
| Emerging transporters of clinical importance: an update from the International Transporter Consortium KM Hillgren, D Keppler, AA Zur, KM Giacomini, B Stieger, CE Cass, ... Clinical Pharmacology & Therapeutics 94 (1), 52-63, 2013 | 402 | 2013 |
| Predicting drug–drug interactions: an FDA perspective L Zhang, YD Zhang, P Zhao, SM Huang The AAPS journal 11 (2), 300-306, 2009 | 330 | 2009 |
| Racial/ethnic differences in drug disposition and response: review of recently approved drugs A Ramamoorthy, MA Pacanowski, J Bull, L Zhang Clinical Pharmacology & Therapeutics 97 (3), 263-273, 2015 | 325 | 2015 |
| Role of organic cation transporters in drug absorption and elimination L Zhang, CM Brett, KM Giacomini Annual review of pharmacology and toxicology 38 (1), 431-460, 1998 | 265 | 1998 |
| Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance MJ Zamek‐Gliszczynski, ME Taub, PP Chothe, X Chu, KM Giacomini, ... Clinical Pharmacology & Therapeutics 104 (5), 890-899, 2018 | 227 | 2018 |
| Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa) L Zhang, ME Schaner, KM Giacomini Journal of Pharmacology and Experimental Therapeutics 286 (1), 354-361, 1998 | 226 | 1998 |
| Why clinical modulation of efflux transport at the human blood–brain barrier is unlikely: the ITC evidence‐based position JC Kalvass, JW Polli, DL Bourdet, B Feng, SM Huang, X Liu, QR Smith, ... Clinical Pharmacology & Therapeutics 94 (1), 80-94, 2013 | 223 | 2013 |
| A regulatory viewpoint on transporter-based drug interactions L Zhang, Y Zhang, JM Strong, KS Reynolds, SM Huang Xenobiotica 38 (7-8), 709-724, 2008 | 204 | 2008 |
| The UCSF‐FDA TransPortal: A Public Drug Transporter Database KM Morrissey, CC Wen, SJ Johns, L Zhang, SM Huang, KM Giacomini Clinical Pharmacology & Therapeutics 92 (5), 545-546, 2012 | 189 | 2012 |
| Scientific perspectives on drug transporters and their role in drug interactions L Zhang, JM Strong, W Qiu, LJ Lesko, SM Huang Molecular pharmaceutics 3 (1), 62-69, 2006 | 186 | 2006 |
| Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment … J Bentz, MP O’Connor, D Bednarczyk, JA Coleman, C Lee, J Palm, ... Drug Metabolism and Disposition 41 (7), 1347-1366, 2013 | 178 | 2013 |
| Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium X Chu, M Liao, H Shen, K Yoshida, AA Zur, V Arya, A Galetin, ... Clinical Pharmacology & Therapeutics 104 (5), 836-864, 2018 | 176 | 2018 |
| Drug interactions evaluation: an integrated part of risk assessment of therapeutics L Zhang, KS Reynolds, P Zhao, SM Huang Toxicology and applied pharmacology 243 (2), 134-145, 2010 | 174 | 2010 |
| Therapeutic protein–drug interactions and implications for drug development SM Huang, H Zhao, JI Lee, K Reynolds, L Zhang, R Temple, LJ Lesko Clinical Pharmacology & Therapeutics 87 (4), 497-503, 2010 | 166 | 2010 |
| Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications Y Zhang, L Zhang, S Abraham, S Apparaju, TC Wu, JM Strong, S Xiao, ... Clinical Pharmacology & Therapeutics 85 (3), 305-311, 2009 | 159 | 2009 |
